After just 42 days, Moderna produced a batch of vaccines ready for clinical trials- from sequence identification through vaccine design, manufacturing, and shipment.
Co-hosted by MIT's Laboratory for Financial Engineering and Golub Center for Finance and Policy, join a conversation with Stéphane Bancel, CEO of Moderna, as he describes the science, business, and policy issues surrounding the first and currently only company with a vaccine for coronavirus in clinical trials at the National Institute of Health (NIH).
Following the lecture, Professor Andrew W. Lo will moderate a fireside chat to discuss this important challenge.
